Table 2.

Timing of SARS-CoV-2 testing and treatment according to days since symptom onset (N = 23).

	Days since symptom onset
Patient No.	First specimen collection (copies/mL)	Negative culture result (copies/mL)	Mechanical ventilation	Antiviral drugs	Corticosteroid therapy
Culture-positive group (N = 7)
P3	12 (2.1 × 10⁹)	24 (4.8 × 10⁶)	11–44	Favipiravir: 3–10	8–18
P7	9 (2.7 × 10⁸)	16 (3.0 × 10⁴)	9–16	Favipiravir: 3–8	4–11; High-dose pulse therapy: 9
P8	10 (1.9 × 10⁵)	N.D.	9–11	None	6–11
P11	9 (4.1 × 10⁷)	13 (4.5 × 10⁷)	7–34	None	4–13
P12	10 (5.3 × 10⁵)	13 (1.8 × 10⁶)	10–14	None	9–15
P14	8 (9.7 × 10⁸)	15 (8.0 × 10⁴)	6–17	Favipiravir: 4–5	4–17; High-dose pulse therapy: 4–6, 12–14
P22	4 (2.7 × 10⁷)	11 (4.7 × 10⁵)	4–29	Remdesivir: 3	3–10; High-dose pulse therapy: 3
Culture-negative group (N = 16)
P1	14 (6.4 × 10³)		10–15	Favipiravir: 1–6	3–16; High-dose pulse therapy: 5–7
P2	11 (7.3 × 10⁵)		8–13	None	5–13
P4	11 (7.0 × 10⁴)		11–18	None	8–11
P5	9 (4.6 × 10⁴)		9–13	Favipiravir: 5–7; Remdesivir: 7–8	7–9; High-dose pulse therapy: 9
P6	11 (4.9 × 10⁶)		11–17	Favipiravir: 7–9; Remdesivir: 9–10;	7–10; High-dose pulse therapy: 10
P9	9 (3.7 × 10⁷)		9–12	Favipiravir: 0–3; Remdesivir: 3–7	3–7
P10	8 (2.7 × 10⁵)		9–25	None	2–8; High-dose pulse therapy: 5–7
P13	12 (3.9 × 10⁶)		9–24	None	7–15; High-dose pulse therapy: 7–8
P15	12 (3.2 × 10³)		3–15	None	3–12
P16	9 (6.5 × 10³)		2–9	None	2–8
P17	10 (2.7 × 10⁶)		5–28	None	9–15
P18	12 (1.6 × 10⁶)		7–25	None	7–13
P19	6 (−)		1–11	None	1–10
P20	10 (1.3 × 10³)		4–20	None	4–10
P21	13 (4.8 × 10⁴)		11–20	None	8–13; High-dose pulse therapy: 9–11
P23	8 (1.1 × 10⁵)		8–13	Favipiravir: 3–6; Remdesivir: 6–7	7–13

High-dose pulse therapy: methylprednisolone 1000 mg/day.

The timing of the first specimen collection, the first specimen collection with a negative culture result, mechanical ventilation, antiviral drug administration, and corticosteroid therapy are shown according to the number of days since symptom onset.

Copies/mL were detected using polymerase chain reaction testing.